Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) has received a ‘Notice of Allowance’ on a US patent application from the United States Patent and Trademark Office protecting its lead drug candidate, OPT-80, which is being developed for the treatment of Clostridium difficile infection, or CDI. The pending patent covers the polymorphic form of the active pharmaceutical ingredient and once issued, will offer patent protection through 2025.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information regarding Optimer can be found at http://www.optimerpharma.com.